Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
159.53B
Market cap159.53B
Price-Earnings ratio
36.41
Price-Earnings ratio36.41
Dividend yield
6.25%
Dividend yield6.25%
Average volume
31.08M
Average volume31.08M
High today
$28.17
High today$28.17
Low today
$27.55
Low today$27.55
Open price
$27.62
Open price$27.62
Volume
31.23M
Volume31.23M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $28.02. The company's market cap stands at 159.53B, with a P/E ratio of 36.41 and a dividend yield of 6.25%.

During the trading session on 2026-10-07, Pfizer(PFE) shares reached a daily high of $28.17 and a low of $27.55. At a current price of $28.02, the stock is +1.7% higher than the low and still -0.5% under the high.

Trading activity shows a volume of 31.23M, compared to an average daily volume of 31.08M.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

PFE News

The Motley Fool 2h
Pfizer Stock: Buy, Sell, or Hold?

Pfizer's (PFE +1.82%) shares have been hovering below $30 for more than two years now. After the company reported some of its best-ever financial performances t...

Pfizer Stock: Buy, Sell, or Hold?
Benzinga 5h
Why Is Pfizer Stock Trading Higher Today? - Pfizer - Benzinga

...

Why Is Pfizer Stock Trading Higher Today? - Pfizer - Benzinga
TipRanks 6h
Pfizer announces FDA approval of TUKYSA regimen for HER2+ breast cancer

Pfizer (PFE) announced that the U.S. Food and Drug Administration has approved TUKYSA in combination with trastuzumab and pertuzumab for the maintenance treatme...

Analyst ratings

59%

of 29 ratings
Buy
31%
Hold
58.6%
Sell
10.3%

More PFE News

Simply Wall St 15h
Pfizer Posted Durable Survival Data In Advanced Bladder Cancer At ESMO 2026

Pfizer (NYSE:PFE) and Astellas reported new data on PADCEV plus pembrolizumab in advanced bladder cancer at ESMO 2026. The partners also presented fresh findin...

Pfizer Posted Durable Survival Data In Advanced Bladder Cancer At ESMO 2026
The Motley Fool 2d
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now

Pfizer (PFE -1.35%) has been a reliable healthcare company to invest in for decades, also providing shareholders with some terrific dividend income along the wa...

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
Benzinga 2d
Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims

A legal filing in Florida accuses pharmaceutical giant Pfizer Inc. (NYSE:PFE) and Chairman and CEO Albert Bourla of deceiving consumers by concealing critical s...

Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
24/7 Wall St. 2d
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Investing Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading...

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Investor's Business Daily 2d
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Technology Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study Licensing Vaxcyte (PCVX) stock catapulted to a nearly two-year high Mond...

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
The Motley Fool 2d
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Is it better to pay a premium for explosive growth or hunt for value in a steady giant? This is the central question for investors choosing between Eli Lilly (L...

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
24/7 Wall St. 3d
Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

Investing Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside Ten consecutive earnings beats and a shrinking COVID hangover have Wall S...

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.